Previous 10 | Next 10 |
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Cassava Sciences To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 investing in Cassava Sciences stock or options between August 18, 2022 and...
2024-02-10 04:24:58 ET Summary Cassava Sciences' handling of data for simufilam is confusing and raises doubts about FDA approval for Alzheimer's disease. Simufilam does not help those with moderate Alzheimer's disease, but may have potential for those with mild cognitive impairme...
ADAS-Cog Scores Were Stable in a Group of Patients with Mild Alzheimer’s Who Received Drug Candidate Simufilam Continuously, Baseline to Month 24. Mild Alzheimer’s Patients Who Received Simufilam Non-Continuously Declined a Group Average of 1 Point on ADAS-Cog, Baseline to...
2024-02-06 21:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against Cassava Sciences, Inc. (NASDAQ: SAVA) for securities law violations. Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might recover those l...
2024-02-03 10:15:00 ET Developing medicines for tricky-to-treat conditions like Alzheimer's disease is tough under the best of circumstances, and as investors in Cassava Sciences (NASDAQ: SAVA) know, sometimes the circumstances are far from ideal. The stock is now down by 23% over t...
2024-01-25 08:00:00 ET Summary Alex Carchidi calls the biotech sector highly risky and speculative, and says diversification is key for investors. Funding is currently difficult to obtain in the biotech industry, but a turnaround is expected. Competitive stories in gene editin...
2024-01-22 11:54:46 ET More on highly-shorted stocks Spirit Airlines: Don't Join The Panic Spirit Airlines: Ch.11 Bankruptcy Could Be A Better Option To Save The Airline Assessing JetBlue Airways During A Time Of Significant Uncertainty Over Spirit Airlines Turmoil ...
2024-01-18 01:02:00 ET Cassava Sciences (NASDAQ: SAVA) stock price has surged hard in the past few months, stinging short-sellers who benefited as it plunged for most of 2023. The shares have surged by more than 106% from the lowest point in November as hopes that its Alzhemer’s ...
2024-01-17 15:09:43 ET More on crowded shorts VinFast's Warm Reception In Contrast To Cold Shoulder Chinese EV Makers Are Getting ImmunityBio: Approval Likely Priced In, Yielding Mostly Risk For Would-Be Buyers Beyond Meat: No Path To Recovery VinFast Auto la...
News, Short Squeeze, Breakout and More Instantly...
Cassava Sciences, Inc. (NASDAQ: SAVA) is one of today's top gainers. The company's shares have moved 24.9% on the day to $12.59. Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...